ClinicalTrials.gg
CompletedNCT02914223Updated Sep 22, 2025

A Study to Evaluate Cenerimod in Healthy Male Subjects

A Phase 1 interventional study of Cenerimod in Healthy Subjects, sponsored by Viatris Innovation GmbH. Completed at 1 site in Netherlands. Open to male participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
45 Years to 65 Years
Sex
Male
01

Study summary

The main objective of the study is to investigate the rate and routes of elimination of cenerimod and the mass balance in urine, feces, and expired air

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure
  • Healthy male subjects aged between 45 and 65 years (inclusive) at screening
  • No findings on the physical examination at screening
  • (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at screening
  • Systolic blood pressure (SBP) 100-145 mmHg and diastolic blood pressure (DBP) 50-90 mmHg, measured on either arm, after 5 min in the supine position at screening and at Day 1 pre-dose
  • Heart rate (HR) 55-90 bpm (inclusive) measured with 12-lead after 5 min in the supine position at screening and at Day 1 pre-dose

Exclusion criteria

Exclusion Criteria:

  • Known to cenerimod or to S1P receptor modulators, or to any of the cenerimod drug formulation
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed)
  • History or clinical evidence suggestive of active or latent tuberculosis including a positive QuantiFERON®-TB test at screening
  • Any cardiac condition or illness (including 12-lead abnormalities) with a potential to increase the cardiac risk of the subject based on the standard 12-lead ECG at screening and at Day 1 pre-dose
  • Participation in another study with a radiation burden of > 0.1 mSv and ≤ 1 mSv in the period of 1 year prior to screening; a radiation burden of ≥ 1.1 mSv and ≤ 2 mSv in the period of 2 years prior to screening, etc. (add 1 year per 1 mSv)
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol
  • Any treatment within 6 weeks or within 5 elimination half-lives of the immunosuppressive treatment, whichever is longer, before study treatment administration
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Treatment and observation period

    On Day 1, subjects will receive a single oral dose of 2 mg 14C-radiolabeled cenerimod. Subjects will be followed for 21 days during which blood, urine, feces, and expired air samples will be collected

    Drug: Cenerimod

  • Experimental
    Extended observation period

    In case, radioactivity recovery does not meet the stopping criteria described in the protocol, the subjects will have to come for a maximum of 7 24-h in-clinic visits during which blood, urine, feces, and expired air samples will be collected

    Drug: Cenerimod

Interventions

  • Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod

06

What researchers measure

Primary outcomes

  1. Cumulative excretion calculated by summing up the daily radioactivity excretion measured by means of liquid scintillation counting in urine, feces, and expired air (if applicable)

    Time frame: From baseline up to a maximum of 99 days

Secondary outcomes

  1. Cmax (maximum plasma concentration) of 14C-radioactivity in whole blood and plasma

    Cmax is derived from the observed plasma concentration-time curves

    Time frame: From baseline up to a maximum of 99 days

  2. tmax (time to reach Cmax) of 14C-radioactivity in whole blood and plasma

    Tmax is derived from the observed plasma concentration-time curves

    Time frame: From baseline up to a maximum of 99 days

  3. t1/2 (terminal half-life)

    Time frame: From baseline up to a maximum of 99 days

  4. Area under the plasma concentration-time curve (AUC) of 14C-radioactivity in whole blood and plasma

    AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity

    Time frame: From baseline up to a maximum of 99 days

  5. Incidence of safety events of interest

    Events of interest are any abnormalities in ECG, vital signs or laboratory test results

    Time frame: From baseline up to a maximum of 99 days

  6. Number of participants with adverse events (AEs)

    Treatment-emergent AEs and treatment emergent serious AEs

    Time frame: From baseline up to a maximum of 99 days

  7. Cenerimod metabolites profiling in plasma

    Relative abundance expressed as percent of cenerimod

    Time frame: From baseline up to a maximum of 99 days

  8. Cenerimod metabolites profiling in urine

    Relative abundance expressed as percent of cenerimod

    Time frame: From baseline up to a maximum of 99 days

  9. Cenerimod metabolites profiling in feces

    Relative abundance expressed as percent of cenerimod

    Time frame: From baseline up to a maximum of 99 days

07

Study locations

1 site
  • PRA Health Science
    Groningen, 9728 NZ, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2016
First posted
Sep 26, 2016
Start
Sep 1, 2016
Primary completionActual
Dec 1, 2016
CompletionActual
Dec 1, 2016
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02914223
Responsible party
Sponsor
First posted
Sep 26, 2016
Start date
Sep 1, 2016
Primary completion
Dec 1, 2016
Completion
Dec 1, 2016
Last update
Sep 22, 2025

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenerimod

Start the discussion